Table 3 Distribution of variables according to the number of post-COVID-19 symptoms in rheumatic disease patients
From: Assessment of symptoms of the post-COVID-19 syndrome in patients with different rheumatic diseases
Parameter mean ± SD or n (%) | Post-COVID-19 symptoms | ||
|---|---|---|---|
1–3 symptoms n (%) n = 27 | ≥ 4 symptoms n (%) n = 38 | P | |
Gender: | |||
Males | 10 (37) | 15 (39.5) | 0.81 |
Females | 17 (63) | 23 (60.5) | |
Age (years) | 43.3 ± 6.5 | 43.6 ± 9.04 | 0.742 |
Disease duration (years) | 8.4 ± 4.2 | 6.6 ± 4.2 | 0.022 |
Hospitalization | 4 (14.8) | 18 (47.4) | 0.0061 |
Biologics use | 12 (44.4) | 1 (2.6) | 0.00011 |
DMARDs stopping | 2 (7.4) | 6 (10.5) | 0.661 |
Steroids use | 14 (51.9) | 36 (94.7) | 0.00011 |
Steroids dose: | |||
Low (< 7.5 mg/d) | 6 (42.9) | 10 (62.5) | 0.321 |
Medium (7.5–30 mg/d) | 8 (57.1) | 22 (61.1) | |
High (> 30 mg/d) | 0 (0) | 4 (11.1) | |
COVID-19 vaccinated | 18 (66.7) | 23 (60.5) | 0.6131 |
Smokers | 8 (29.6) | 23 (60.5) | 0.0141 |